Source-grounded facts extracted from INTELLIGENT BIO SOLUTIONS INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
INTELLIGENT BIO SOLUTIONS INC. entered into Purchase Agreement with 14 investors valued at $220,585 (effective 2022-12-21).
“On December 21, 2022, Intelligent Bio Solutions Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with 14 investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors in a Regulation S private placement (the “Transaction”) (i) 176,462 shares of the Company’s Series D Convertible Preferred Stock (the “Preferred Stock”), par value $0.01 per share (the “Preferred Stock”), and (ii) 529,386 warrants (the “Warrants”), with each Warrant representing the right to purchase one share of the Company’s common stock (“Common Stock”).”
Earnings Releases
INTELLIGENT BIO SOLUTIONS INC. reported preliminary financial results for first financial quarter ended September 30, 2022.
“On November 9, 2022, Intelligent Bio Solutions Inc. (the “Company”), issued a press release (the “Press Release”) announcing financial results for the three months ended September 30, 2022.”
Steven Boyages changed role as Interim Chief Executive Officer at INTELLIGENT BIO SOLUTIONS INC..
“Dr. Steven Boyages, who is stepping down as the Company’s Interim Chief Executive Officer.”
Harry Simeonidis was elected as President and Chief Executive Officer at INTELLIGENT BIO SOLUTIONS INC..
“elected Harry Simeonidis, who currently serves as the Company’s President Asia Pacific, Sales and Marketing, as the Company’s President and Chief Executive Officer, effective as of October 26, 2022.”
David Jenkins was appointed as Director at INTELLIGENT BIO SOLUTIONS INC..
“each of Jason Isenberg and David Jenkins, each being designee of the Investors under the Investors’ Rights Agreement, was appointed as a member of the Board.”
Jason Isenberg was appointed as Director at INTELLIGENT BIO SOLUTIONS INC..
“each of Jason Isenberg and David Jenkins, each being designee of the Investors under the Investors’ Rights Agreement, was appointed as a member of the Board.”
Leon Kempler resigned as Director at INTELLIGENT BIO SOLUTIONS INC..
“On April 27, 2022, Leon Kempler, a member of the Board of Directors (the “Board”) of GBS Inc. (the “Company”), resigned as a member of the Board effective as of such date.”
Tom Parmakellis resigned as member of the Board of Directors at INTELLIGENT BIO SOLUTIONS INC..
“On March 19, 2022, Tom Parmakellis, a member of the Board of Directors (the “Board”) of GBS Inc. (the “Company”), resigned as a member of the Board effective as of such date.”
Prof. Jonathan Sessler resigned as Director at INTELLIGENT BIO SOLUTIONS INC..
“On February 22, 2022, Prof. Jonathan Sessler, a member of the Board of Directors (the “Board”) of GBS Inc. (the Company”), resigned as a member of the Board effective as of such date.”
Harry Simeonidis was appointed as President Asia Pacific, Sales and Marketing at INTELLIGENT BIO SOLUTIONS INC..
“Harry Simeonidis, who served as CEO and President of the Company, vacated these positions prior to Professor Boyages’ appointment as Interim CEO and was appointed to the position of President Asia Pacific, Sales and Marketing, effective October 29, 2021.”
Steven Boyages was appointed as Interim Chief Executive Officer at INTELLIGENT BIO SOLUTIONS INC..
“the board of directors (the “Board”) of GBS Inc. (the “Company”) appointed Professor Steven Boyages, the Chairman of the Board, to the additional position of Interim Chief Executive Officer of the Company, effective immediately.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.